Schematic representation of antiangiogenic effects of imatinib on DLBCL. On the left, intact lymphoma vasculature is represented. On the right, in the presence of imatinib, PDGFRβ⁺ pericytes (P) are depleted via imatinib binding to the PDGFRβ receptor, leading to EC apoptosis, disruption of tumor vessel (V) integrity, and lymphoma (L) regression.